Taming THC

Taming THC

THC has been the focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. Today, the contributions of CBD and terpenes are being scientifically demonstrated.
THC has been the focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. Today, the contributions of CBD and terpenes are being scientifically demonstrated.

Published in full in the British Journal of Pharmacology.

Abstract: Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study.

This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human diets that have been designated Generally Recognized as Safe by the US Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent, and affect animal and even human behaviour when inhaled from ambient air at serum levels in the single digits ng·mL−1. They display unique therapeutic effects that may contribute meaningfully to the entourage effects of cannabis-based medicinal extracts. Particular focus will be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus).

Scientific evidence is presented for non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index. Methods for investigating entourage effects in future experiments will be proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant.

Read full abstract

This piece was reprinted by Project CBD with permission. It may not be reproduced in any form without approval from the source.

Revision date: 
Jan 29, 2014

Find CBD near you

Browse hundreds of retail locations for quality CBD products.

Search

News & Reports

Climate change and cannabis commerce point to a green future

Top Conditions

In compiling a list of conditions that CBD may help, we examined hundreds of peer-reviewed articles in scientific journals.

Cannabis Conversations

Project CBD talks with Dr. Bonni Goldstein about whole plant cannabis remedies, nonintoxicating cannabinoids, and cancer care for children.
Expert cannabis botanist and geneticist Ryan Lee talks to Project CBD about breeding cannabis, THC & CBD content, and how to interpret lab data.
Project CBD speaks with Dr. Rachel Knox about "endocannabinology," THC/CBD synergies, and whole food nutrition.

Thanks to our sponsors and supporters:

Top Stories